ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
BARYTHRAX inj. is the first anthrax vaccine globally to be developed using recombinant protein technology. Unlike ...
WASHINGTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Recombinant DNA Technology Market finds that the increasing strategic collaborations among key ...
The production of antibodies has thus far been limited to a small number of species, most often murine, which has led to availability and scalability challenges for scientists. Technology Networks ...
The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...
The market for Recombinant DNA Technology was valued at US$ 445 billion in 2021 and is anticipated to grow at a CAGR of 7.2% through 2032. Recombinant DNA technology’s introduction has changed how ...
Marketresearch.biz reports that the Recombinant DNA Technology Market size is expected to be worth around USD 1288.5 Bn by 2032 from USD 743.6 Bn in 2022, growing at a CAGR of 5.8% during the forecast ...
Antibody engineering and production are essential tools in drug discovery, providing powerful and specific therapeutics and diagnostic/prognostic materials for various diseases. Antibodies are ...
Thought LeadersDr. Amy Sheng, Dr. Lurong PanTechnical Account Manager, CEOSino Biological Inc., Ainnocence In this interview, NewsMedical talks to Dr. Amy Sheng, a technical account manager at Sino ...
THE STRUCTURE AND FUNCTION OF RECOMBINANT HUMANIZED TYPE III COLLAGEN AS WELL AS ITS RELATED PRODUCT approved by CHINA NMPa for COSMETICS USE (ADAPTED FROM THE AUTHORS’ PUBLICATION IN Biochemical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback